Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
RavenQuest BioMed Inc. (RVVQF)
Vancouver, BC, CA
RavenQuest BioMed Inc. operates primarily within the cannabis industry. Its core activities include the cultivation of cannabis, offering management and consulting solutions, and conducting specialized research and development. The company structures its operations into two distinct areas: a consulting division and a segment dedicated to the growth and sale of medical cannabis. Its products are available under the brand names Lore Cannabis and Bloomera. The entity, originally known as Ravencrest Resources Inc., rebranded to RavenQuest BioMed Inc. in September 2017. Founded in 1987, its corporate headquarters are situated in Vancouver, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +900.00% | -94.71% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.90% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+1,018.8% ★ Q3'19: +312.9% (vs Q3'18)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-230.0% Q3'19: +21.1% (vs Q3'18)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-2,580.1% Q3'19: -294.9% (vs Q3'18)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-2,318.4% Q3'19: -313.5% (vs Q3'18)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-82.6% Q3'19: -25.7% (vs Q3'18)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+180.3% Q3'19: +24.3% (vs Q3'18)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.49× Q3'19: -2.60× (vs Q3'18)
| Metric |
Oct 2018 actual |
Oct 2019 actual |
Oct 2020 actual |
Oct 2021 actual |
Oct 2022 actual |
Oct 2023 actual |
|---|---|---|---|---|---|---|
| Revenue |
1.26M
est: 1.71M (-26.3%)
|
43.84M
est.
|
75.27M
est.
|
194.99M
est.
|
220.80M
est.
|
220.64M
est.
|
| EBITDA |
-27.26M
est: 341.0K (-8,094.3%)
|
8.77M
est.
|
15.05M
est.
|
39.00M
est.
|
44.16M
est.
|
44.13M
est.
|
| EBIT |
-29.14M
est: 341.0K (-8,645.9%)
|
8.77M
est.
|
15.05M
est.
|
39.00M
est.
|
44.16M
est.
|
44.13M
est.
|
| Net Income |
-30.47M
est: -8.18M (-272.6%)
|
5.46M
est.
|
—
est.
|
—
est.
|
—
est.
|
—
est.
|
| SGA |
11.19M
est: 5.98M (+87.0%)
|
153.80M
est.
|
264.10M
est.
|
684.11M
est.
|
774.66M
est.
|
774.08M
est.
|
| EPS |
-0.33
est: -0.09 (-267.3%)
|
0.06
est.
|
—
est.
|
—
est.
|
—
est.
|
—
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Allen Cross | Chief Financial Officer | 57.9K | male |
| Andy Schinke | Head of Sales & Product Acquisition | — | — |
| Marla K. Ritchie | Corporate Secretary | — | female |
| Mathieu Mcdonald | Head of Corporate Communications | — | male |
| Shayne Taker | Head of Orbital Garden Mfg & Procurement | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RVVQF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
